Skip to content Skip to footer

ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)

Menu
Menu

Home

Main menu

Trending

Latest Issue

Articles
Urine C-reactive protein content and non-invasive molecular grading of renal cell carcinoma
Introduction Renal cell carcinoma (RCC) accounts for 4.2% of adult malignancies and is the 10th leading cause of cancer deaths in the United States.1 In the United States in 2024, more than 81,000 new cases were diagnosed and more than 14,300 died, due…
March 16, 2019
Articles
Practice-Ready Molecular Imaging in Renal Cell Carcinoma
Abstract : BACKGROUND: Renal cell carcinoma (RCC) is the most common kidney malignancy, often associated with poor prognosis due to late-stage diagnosis and metastasis. Recent research has identified PIWI-interacting RNAs (piRNAs) and PIWI-like proteins as potential biomarkers and therapeutic targets in cancer,…
February 20, 2026
Articles
The New Frontier: Advancements in Kidney Cancer Treatment
Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD Dear colleagues, The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. As editors,…
February 20, 2026
Articles
Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…
February 20, 2026
Articles
The Future of RCC Treatment
Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD The Kidney Cancer Journal is pleased to receive and review the expert consensus manuscript stemming from the IKCSEU24 Think…
February 21, 2026

Current Trends

ESMO 2026 SNEAK PEEK
Articles
█ For kidney cancer, ESMO 2026 has one of its most concentrated programmes in years. Nearly all of the practice-relevant renal data come on a single day, Sunday, October 25. The morning Proffered Paper session puts both phase 3 belzutifan readouts, a…
Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC
Articles
#Equal Contributions as Senior/Supervising Authors ϮAddress Correspondence: Abhishek A. Chakraborty, PhD Department of Cancer Sciences, Cleveland Clinic, Cleveland OH E-mail: chakraa@ccf.org Conflict of Interest: The authors declare no conflict of interest with this study. INTRODUCTION Clinical outcomes for patients…
EXPERT COMMENTARY – ASCO26
Articles
Perspectives synthesized from ASCO 2026 presenter and discussant sessions and post-meeting expert commentary. Prepared for educational purposes by the Kidney Cancer Journal editorial team. Toni K. Choueiri, MD, FASCO. Dana-Farber Cancer Institute, Boston, MA. Presenter — LITESPARK-022 and KEYNOTE-564 ctDNA Analysis…

Explore Our New Articles